Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Veridex has announced that its licensing collaborator, Laboratory Corporation of America Holdings, has launched a new gene methylation test for prostate cancer.
Subscribe to our email newsletter
The new assay uses the biological specificity of ‘DNA methylation’ in prostate cancer, detecting the methylation of the gene GST-Pi. Methylation is a modification of DNA that occurs primarily in cancer. Veridex is developing the methylation markers in this tissue assay, GST-Pi, along with other markers, for a urine-based screening test for prostate cancer.
LabCorp licensed the methylation technology from Veridex in 2007. Veridex licensed this technology from OncoMethylome Sciences.